A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection.

@article{Breton2007ARN,
  title={A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection.},
  author={Marie Breton and Chenqi Zhao and Marc A. Ouellette and Michel J Tremblay and Barbara Papadopoulou},
  journal={The Journal of general virology},
  year={2007},
  volume={88 Pt 1},
  pages={217-25}
}
Live-vector human immunodeficiency virus (HIV) vaccines are an integral part of a number of HIV vaccine regimens currently under evaluation that have yielded promising results in pre-clinical testing. In this report, a non-pathogenic protozoan parasitic vector, Leishmania tarentolae, which shares common target cells with HIV-1, was used to express full-length HIV-1 Gag protein. Immunization of BALB/c mice with recombinant L. tarentolae led to the expansion of HIV-1 Gag-specific T cells and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Technical tips online. Simple and efficient panning of transfected cell populations expressing a cell surface marker

J. D. Norton
Trends Genet • 1997
View 4 Excerpts
Highly Influenced

Progress toward an HIV vaccine.

Annual review of medicine • 2005
View 3 Excerpts

Live attenuated HIV vaccines: pitfalls and prospects.

Current opinion in infectious diseases • 2004
View 1 Excerpt

Similar Papers

Loading similar papers…